Is This Biotech Stock a Buy After Its Massive Rally?
This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives.
Overview
Viking Therapeutics (NASDAQ: VKTX) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries serious risk, especially as a better-funded rival gains a head start. The upside could be substantial, but only if the data, timing, and buyer interest line up.
Stock prices used were the market prices of June 26, 2026. The video was published on July 7, 2026.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.